for the Bleeding Effected by Direct Oral Anticoagulants (BLED-AC) Study Group BACKGROUND: Direct oral anticoagulants (DOACs) have expanded the armamentarium for antithrombotic therapy. Although DOAC-related major bleeding was associated with favorable outcomes compared with warfarin in clinical trials, warfarin effects were reversed in < 40% of cases, raising concerns about the generalizability of this finding.
The availability of the direct oral anticoagulants (DOACs) dabigatran, rivaroxaban, apixaban, and edoxaban represents an expansion of the clinical armamentarium for stroke prevention in atrial fibrillation. Despite post hoc analyses of randomized trials showing equal or lower mortality following DOAC-associated major bleeding compared with bleeding from warfarin, 1,2 rates of attempted reversal in the warfarin arm were < 40% at best. 1 It is unknown whether these outcomes are generalizable to settings with higher rates of attempted warfarin reversal. 3, 4 Data from one DOAC registry suggest that very few patients required coagulation products in the setting of major bleeding 5, 6 ; however, the lack of a concurrent warfarin cohort, the relatively low number of events, and the selective nature of patient enrollment make these results susceptible to bias. 7 Furthermore, although the regulatory approval of targeted reversal agents such as idarucizumab may address the historical inability to actively reverse DOACs, 3, 4 phase III investigations of these agents in bleeding patients did not involve a comparator arm, and it is possible that placebo-controlled studies will not be performed. 4, 8 Therefore, it is important to establish blood product use and patient outcomes in unselected DOAC-associated major bleeding in the pre-antidote era to fully evaluate the clinical effectiveness of these agents.
Given the lack of comparative evidence following major bleeding in routine practice, we undertook Bleeding Effected by Direct Oral Anticoagulants (BLED-AC), a multicenter cohort study involving chart review with subsequent administrative data linkage, to determine and compare management strategy and outcomes in the treatment of DOAC-and warfarin-related major bleeding episodes.
Methods

Study Population
This was a cohort study of patients who experienced DOAC-or warfarin-associated major bleeding. We used existing hospital records to identify all cases of oral anticoagulant-associated bleeding events involving individuals aged $ 66 years presenting to one of five tertiary care hospitals across three cities in Ontario, Canada with a combined catchment area of approximately 4 million residents. Age cutoff was chosen to enable linkage to administrative databases. Data capture spanned from October 2010 to March 2015. The start date was chosen to coincide with the Health Canada approval date of dabigatran, the first DOAC to enter the Canadian market for stroke prophylaxis in atrial fibrillation. 9 Research ethics boards at institutions involved approved the study, as did the Institutional Review Board at Sunnybrook Health Sciences Centre, Toronto, Canada.
An oral anticoagulant-related major bleeding episode was defined as (1) a person presenting to the hospital with documented bleeding, (2) use of dabigatran, rivaroxaban, apixaban, or warfarin within 3 days of presentation, (3) a documented diagnosis of atrial fibrillation or flutter, and (4) fulfilling one of the following criteria:
1. International Society for Thrombosis and Haemostasis major bleeding definition components (hemoglobin drop $ 2 g/dL, involvement of a critical organ [intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome], or a fatal bleeding episode). 10 2. Transfusion of blood products or use of a specific reversal agent.
3. An event resulting in hospitalization.
11
Exclusion criteria included an initial presentation that did not involve hemorrhage (biochemical coagulopathy without signs, symptoms, or diagnosis of bleeding; bleeding that began in the hospital; or periprocedural anticoagulant bridging) and a history of prosthetic heart valve (mechanical or bioprosthetic) as use of DOACs are approved in this setting.
Data Sources
A comprehensive chart review was undertaken using electronic medical records housed at the health records and decision support departments of participating hospitals. The International Classification of Diseases, Tenth Revision, Canadian Coding Standards was used for identification of bleeding cases using a series of validated codes present in any diagnosis field. 12 In the validation study, the International Classification of Diseases coding algorithm was found to have 93% sensitivity for definite bleeding based on subsequent chart review, including physician documentation of directly observed bleeding, imaging results consistent with bleeding, or finding of a bleeding source combined with signs of active bleeding (eg, observed duodenal ulcer with melena). 12 For each eligible case, baseline clinical characteristics (vital signs, laboratory investigations, type and dose of oral anticoagulant, concomitant medications) and blood use data were abstracted. To ensure comprehensiveness, scanned chart documents (order sheets, emergency triage records, progress notes) were reviewed in addition to dictated or typed notes or encounter summaries. Transfusion data were available at all participating sites through either transfusion records or electronic medical records, or both. The chart abstraction manual used in this study is included in e-Appendix 1. Database, which contained all visits to acute and rehabilitation institutions, was used to determine comorbid medical conditions, in-hospital deaths for hospitalized patients, and the number of bleeding-related hospitalizations within 5 years for each case. 3. The National Ambulatory Care Reporting System, which contained all visits to the ED, was used to determine in-hospital deaths for patients presenting to the ED. 4. The Ontario Health Insurance Plan database, which contained physician services, was used in conjunction with the Discharge Abstract Database in a 5-year "look-back" window to verify previous hospital or ambulatory atrial fibrillation diagnoses among all included cases. 5. The Registered Persons Database, which captures demographic and vital information on all Ontarians, was used to determine patient demographic characteristics and 30-day mortality.
Validation of chart abstraction across sites was achieved by interrater reliability testing. Agreement on all data fields across five participating sites was 98%, representing high-quality data. 13 Any uncertainty on cohort inclusion or chart abstraction fields was adjudicated by an expert committee consisting of investigators from each participating hospital. The quality of data generated by individual hospital decision support units and captured in the Discharge Abstract Database and the National Ambulatory Care Reporting System has been validated through data reabstraction and interrater reliability studies by the Canadian Institute for Health Information.
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Outcomes
The primary study outcome was treatment strategy, including the use of reversal agents and blood products, during the course of the hospital encounter in DOAC-and warfarin-related bleeding events. Specifically, rates and dosages of vitamin K, tranexamic acid, fresh frozen plasma, packed red blood cells, platelets, prothrombin complex concentrates (activated and nonactivated) and recombinant factor VIIa were evaluated. Secondary outcomes include in-hospital and 30-day mortality.
Statistical Analysis
Differences across DOAC-and warfarin-related bleeding events on baseline parameters were compared using standardized differences, an approach frequently used in observational studies; values > 0.1 are generally considered meaningful. 16 Anatomic sites of bleeding were compared between DOAC-and warfarin-related bleeding events using the Fisher exact test. Poisson regression with robust standard errors was used to calculate adjusted relative risks in binary outcomes (mortality, receipt of reversal agents), 17, 18 whereas linear regression was used to determine beta-coefficients for continuous outcomes (dosage of reversal agents). Covariates included in the regression models, determined a priori, consisted of age, chronic kidney disease status, CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age [$ 75 years]), diabetes, stroke/ transient ischemic attack, vascular disease, age [65-74 years], sex [female] score) and HAS-BLED (hypertension, abnormal renal/ liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly [> 65 years]) components, number of previous admissions for bleeding, and comorbid disease burden (Charlson comorbidity index). The use of administrative databases for identifying these covariates has been validated. 11, [19] [20] [21] To account for multiple events, sensitivity analyses were performed. First, an analysis restricted to cases with no ED presentation or hospital admission for bleeding within 30 days of the index date was performed for each outcome to limit cases involving recent hemorrhage. Second, we repeated the Poisson analysis previously described while specifying the patient number, rather than the case number, as the subject variable. 17 Cells with sample sizes of five or less were suppressed to prevent risks of reidentification. A type 1 error rate of 0.05 was used as a threshold for statistical significance. Sample size calculations are included in e-Appendix 1. All analyses were completed using SAS statistical software, version 9.4 (SAS Institute).
Results
During our study period, a total of 19,061 consecutive cases with hemorrhage diagnoses were identified through medical records and screened; 2,002 cases (10.5%; 460 DOAC and 1,542 warfarin events) involving 1,799 patients were eligible for inclusion in the analysis (Fig 1) . Among DOAC cases, 245 involved dabigatran (53.3%), including less than six cases involving both dabigatran and rivaroxaban within 3 days of presentation (in accordance with Institute for Clinical Evaluative Sciences privacy policy, the exact number was suppressed to ensure confidentiality). One hundred fiftyfive cases (33.7%) involved rivaroxaban, and 60 cases were associated with apixaban (13.0%). Patients with oral anticoagulant-related major bleeding had a mean age of 81.2 years (SD, 7.1 years), an average CHA 2 DS 2 -VASc score of 4.4 (95% CI, 4.4-4.5), and a median HAS-BLED score of 3 (interquartile range [IQR], 2-3). Presenting blood pressure readings were similar between patients who received DOACs and those who received warfarin, and the median initial hemoglobin value was > 100 g/L in both groups (Table 1) .
Intracranial hemorrhage composed a lower proportion of major bleeding involving DOACs compared with warfarin, especially subdural hematomas (13.3% vs 19.0%; P < .01) ( Table 2 ). Meanwhile, a higher proportion of GI bleeding was seen in the DOAC cohort, especially involving the lower GI tract (31.1% vs 17.3%; P < .01). Nadir values of hemoglobin were similar between DOACs (median, 92; IQR, 76-114) and warfarin (median, 94; IQR, 77-114).
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Blood Product Use
Among patients who had DOAC-and warfarinassociated major bleeding events, 278 (60.4%) and 1,014 (65.8%), respectively, received blood products (adjusted risk ratio [aRR] 0.92; 95% CI, 0.85-1.00). Packed red blood cells were the product type used most frequently in DOAC events and were used significantly more often than that they were in warfarin events (Table 3) . Conversely, rates of prothrombin complex concentrate (40.7%), vitamin K (72.9%), and fresh frozen plasma (17.9%) use were higher in patients who received warfarin. Notably, prothrombin complex concentrates (nonactivated) were used in 12.3% of DOAC cases, whereas activated prothrombin complex concentrates and recombinant factor VIIa were used in 5.2% and 2.2% of DOAC-associated bleeding events, respectively. Units and doses of packed red blood cells, prothrombin complex concentrates, fresh frozen plasma, platelets, and recombinant factor VIIa did not differ between the two groups (Table 3) .
Clinical Outcomes
Overall, 9.8% of patients with a DOAC-associated major bleeding episode and 15.2% of those with a warfarinassociated major bleeding episode died in the hospital (P < .0001). After adjusting for age, chronic kidney disease status, CHA 2 DS 2 -VASc and HAS-BLED components, number of previous admissions for bleeding, and Charlson comorbidity index, the aRR for in-patient mortality was 0.66 (95% CI, 0.49-0.89) for DOAC major bleeding events compared with warfarin major bleeding events. All-cause 30-day mortality was 12.6% (DOAC bleeding events) and 16.3% (warfarin bleeding events), with a corresponding aRR that did not achieve statistical significance (aRR, 0.79; 95% CI, 0.61-1.03) (Fig 2) .
Sensitivity Analysis
Results for blood product use and administration of vitamin K were consistent when analyzed by sensitivity analyses (e-Appendix 1). When restricted to cases with no hospitalization record for bleeding within 30 days of the index date to limit cases involving recent hemorrhage, the patients hospitalized with a DOAC bleeding event had a lower risk of in-patient mortality (aRR, 0.66; 95% CI, 0.48-0.89) and no statistically significant difference in risk of 30-day mortality (aRR, 0.78; 95% CI, 0.60-1.02). Similar results were observed using Poisson regression with correction of multiple events (e-Appendix 1).
Discussion
In this study of > 2,000 major bleeding events associated with DOACs and warfarin, we found a higher rate of packed red blood cell transfusions in DOAC bleeding events compared with warfarin events, reflecting the GI predominance of the bleeding pattern. This is supported by our observation that among patients requiring red blood cell transfusions, a similar number of products were used between the two groups. Meanwhile, activated prothrombin complex concentrates and recombinant factor VIIa were used in less than one in 13 cases to control DOAC-associated major bleeding events. We also found high rates of use for vitamin K and prothrombin complex concentrates in warfarinassociated bleeding events. Despite this, in-patient mortality from major bleeding, the outcome most proximally related to anticoagulant exposure and directly influenced by its effects, was lower for patients receiving DOACs compared with those receiving warfarin. Although difference in 30-day mortality between the two groups was not statistically significant, the 95% CI of the estimated relative risk suggests that it is likely this difference in mortality persists at 30 days.
Most DOAC studies in routine clinical care focus on rates of major bleeding occurrence [22] [23] [24] [25] rather than In accordance with Institute for Clinical Evaluative Sciences privacy policies, in cases in which the number of total users is # 5, this number has been suppressed to ensure confidentiality. In these cases, related percentages were reported using n # 5. In cases in which there is only one record being suppressed, the other record with lowest value has been suppressed as well to avoid residual disclosure issues. management and outcomes following such hemorrhage. Important differences exist between our results and those reported in postmarketing cohorts published to date on management and outcomes of DOACassociated major bleeding. 5, 6 No activated prothrombin complex concentrates or factor VIIa was used in the management of 66 rivaroxaban-and 11 dabigatranassociated major bleeding events included in a prospective registry based in Dresden, Germany, 5, 6 whereas they were used in 7.2% of DOAC-related major bleeding events in our study. Furthermore, all-cause mortality following major bleeding involving DOACs was lower in the Dresden study: 10.5% at 90 days compared with 12.6% at 30 days in the current study. In addition to differences in sample size (460 cases in the current study compared with 77 in the Dresden cohort), the discrepancy in management and outcome data can be explained by the inclusion of consecutive major bleeding cases in our study that allowed capture of patients with the full clinical spectrum of major hemorrhage, an especially relevant issue, as previous work involving clinical registries requiring consent demonstrated that enrolled patients were often at lower risk compared with patients who were unable or unwilling to provide consent. 26 The prevalence of DOAC-associated major bleeding events in our study included the use of dabigatran, rivaroxaban, and apixaban, in descending order, reflecting the duration of Table 1 legend for expansion of other abbreviations. a Sites of bleeding are not mutually exclusive. b In accordance with Institute for Clinical Evaluative Sciences privacy policies, in cases in which the number of total users is # 5, this number has been suppressed to ensure confidentiality. In these cases, related percentages were reported using n # 5.
chestjournal.org market authorization and prescription trends of these medications.
In our study, the uptake of evidence-based warfarin reversal was markedly higher than that reported in DOAC trials. was similar to clinical outcomes observed in our study. As specific DOAC reversal agents were evaluated without a comparator group due to ethical considerations, ongoing comparisons with our results from the pre-antidote era may help inform the appropriate use of these agents, especially given their acquisition cost. 29 Our study has strengths that address criticisms of previous DOAC post-marketing surveillance. [30] [31] [32] In particular, we combined the powerful granularity of chart review with the longitudinal nature of administrative data. However, there are several limitations. The hospitals involved serve as regional referral centers, and outcomes of the study may not extend to a different setting. However, the institutions included were also the first point of emergency medical contact for residents in the cities where they were located and likely represent settings of initial uptake for target-specific DOAC reversal agents. In addition, our population involved patients undergoing thromboprophylaxis for atrial fibrillation and cannot be directly extrapolated to other indications for anticoagulation therapy. Finally, our observational design is susceptible to immortal time bias and confounding by indication. In immortal time bias, 33 patients receiving warfarin must have survived until October 2010 (start of chart review and date of first DOAC approval) to be included, thus excluding those who died prior to this capture period. Meanwhile, patients who received DOACs had no access to the drug prior to our timeline and are not susceptible to this risk-attenuating effect. In confounding by indication, clinicians may selectively prescribe DOACs or warfarin based on an unmeasurable or unknown factor. However, the rates of previous bleeding at baseline were remarkably similar across both groups, raw and adjusted outcomes were consistent with each other and data from trials, and sensitivity analyses did not alter our results.
Conclusions
In a large cohort of unselected patients presenting with anticoagulant-related hemorrhage in routine clinical practice, red blood cell transfusion was used more frequently in cases involving DOACs compared with those involving warfarin, reflecting the former's GI pattern of bleeding. However, the rate of overall blood product use and quantity of products transfused did not differ between the two groups. In-hospital mortality was lower with DOACs compared with warfarin, despite high rates of warfarin reversal. This is consistent with clinical trial findings and suggests that patients receiving these novel agents do not experience excess harm compared with warfarin in the real-world context, even with the lack of specific antidotes. Our findings will serve as useful baseline data for comparison of effectiveness and cost-effectiveness of drug-specific reversal agents to guide their optimal use. chestjournal.org
